Cellino: Automating complex production, differentiation of iPS cells into cell therapies
Via $80M A round for manufacturing play, Bayer deepens its reach into next-gen cell therapy technologies
Cellino is aiming to bring iPS cell-derived cell therapies to the masses through an automated manufacturing process that can commercially scale the reprogramming of stem cells into therapeutic cells. That goal meshes well with Bayer’s push into cell therapies.
Cellino Biotech Inc. announced Tuesday that it raised $80 million in a series A round co-led by Leaps by Bayer, the strategic investment arm of Bayer AG (Xetra:BAYN), 8VC and Humboldt Fund. The deal brings the Cambridge, Mass.-based biotech’s total money raised to $96 million, including a seed round from existing investors The Engine and Khosla Ventures. ...